MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Cogent Biosciences Inc

Open

14.99 5.94

Overview

Share price change

24h

Current

Min

14.09

Max

14.98

Key metrics

By Trading Economics

Income

-1.5M

-74M

Profit margin

-1,582.642

Employees

205

EBITDA

1.7M

-72M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+55.06% upside

Dividends

By Dow Jones

Next Earnings

10 lis 2025

Market Stats

By TradingEconomics

Market Cap

298M

2B

Previous open

9.05

Previous close

14.99

Technical Score

By Trading Central

Confidence

Bearish Evidence

Cogent Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 paź 2025, 23:30 UTC

Hot Stocks

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 paź 2025, 21:21 UTC

Earnings

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 paź 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 paź 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 paź 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 paź 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 paź 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 paź 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 paź 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 paź 2025, 22:54 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Scales's JV Buyout Lauded by Bull -- Market Talk

2 paź 2025, 22:54 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Forex and Fixed Income Roundup: Market Talk

2 paź 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 paź 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 paź 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 paź 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

2 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 paź 2025, 20:49 UTC

Acquisitions, Mergers, Takeovers

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 paź 2025, 20:00 UTC

Acquisitions, Mergers, Takeovers

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 paź 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 paź 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 paź 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 paź 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 paź 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 paź 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 paź 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 paź 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 paź 2025, 18:43 UTC

Acquisitions, Mergers, Takeovers

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer Comparison

Price change

Cogent Biosciences Inc Forecast

Price Target

By TipRanks

55.06% upside

12 Months Forecast

Average 21.91 USD  55.06%

High 30 USD

Low 11 USD

Based on 12 Wall Street analysts offering 12 month price targets forCogent Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

10

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

4.88 / 5.87Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
help-icon Live chat